You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Harvard Business School
Mallinckrodt
Baxter
AstraZeneca

Last Updated: February 27, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYDROCORTISONE SODIUM SUCCINATE

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Hydrocortisone Sodium Succinate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002757 TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma Completed Children's Cancer and Leukaemia Group Phase 3 2001-06-01 RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in children with non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for children who have non-Hodgkin's lymphoma.
NCT00002757 TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma Completed National Cancer Institute (NCI) Phase 3 2001-06-01 RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in children with non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for children who have non-Hodgkin's lymphoma.
NCT00002757 TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma Completed Societe Francaise Oncologie Pediatrique Phase 3 2001-06-01 RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in children with non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for children who have non-Hodgkin's lymphoma.
NCT00002757 TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma Completed Children's Oncology Group Phase 3 2001-06-01 RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in children with non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for children who have non-Hodgkin's lymphoma.
NCT00002805 Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 2 1997-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with acute myeloid leukemia or myelodysplastic syndrome in first relapse or who did not achieve first remission.
NCT00002805 Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed Children's Oncology Group Phase 2 1997-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with acute myeloid leukemia or myelodysplastic syndrome in first relapse or who did not achieve first remission.
NCT00707083 Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Active, not recruiting Prince of Wales Hospital, Shatin, Hong Kong Phase 3 2008-05-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia. PURPOSE: This randomized clinical trial is studying the side effects of two combination chemotherapy regimens and to see how well they work in treating children with newly diagnosed acute lymphoblastic leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Hydrocortisone Sodium Succinate

Condition Name

Condition Name for Hydrocortisone Sodium Succinate
Intervention Trials
Leukemia 4
Sepsis 2
Lymphoma 2
B Acute Lymphoblastic Leukemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Hydrocortisone Sodium Succinate
Intervention Trials
Leukemia 6
Precursor Cell Lymphoblastic Leukemia-Lymphoma 4
Leukemia, Lymphoid 4
Lymphoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Hydrocortisone Sodium Succinate

Trials by Country

Trials by Country for Hydrocortisone Sodium Succinate
Location Trials
United States 75
Canada 10
Australia 6
New Zealand 2
China 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Hydrocortisone Sodium Succinate
Location Trials
Tennessee 3
Pennsylvania 3
Oregon 2
Minnesota 2
Missouri 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Hydrocortisone Sodium Succinate

Clinical Trial Phase

Clinical Trial Phase for Hydrocortisone Sodium Succinate
Clinical Trial Phase Trials
Phase 3 6
Phase 2 2
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Hydrocortisone Sodium Succinate
Clinical Trial Phase Trials
Recruiting 4
Completed 3
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Hydrocortisone Sodium Succinate

Sponsor Name

Sponsor Name for Hydrocortisone Sodium Succinate
Sponsor Trials
National Cancer Institute (NCI) 5
Children's Oncology Group 3
Emory University 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Hydrocortisone Sodium Succinate
Sponsor Trials
Other 10
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Harvard Business School
McKinsey
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.